3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
59
Neoplasm Metastasis
24
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
7
Triple Negative Breast Neoplasms
5
Adenocarcinoma
5
Recurrence
3
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Esophageal Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Salivary Gland Neoplasms
2
Meningeal Carcinomatosis
2
HER2-positive Breast Cancer
2
Colonic Neoplasms
2
Breast Cancer With Brain Metastasis
2
Advanced Breast Cancer
2
Adenocarcinoma Of Esophagus
2
Uterine Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Solid Cancer
1
Sarcoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Osteosarcoma
1
Interventions
Temozolomide
156
Bevacizumab
69
Radiotherapy
61
Magnetic Resonance Spectroscopy
59
Irinotecan
31
Surgical Procedures, Operative
23
Radiation
23
Carboplatin
23
Specimen Handling
20
Carmustine
20
Nivolumab
19
Biopsy
17
Lomustine
16
Aminolevulinic Acid
15
Radiotherapy, Intensity-Modulated
13
Cyclophosphamide
13
trametinib
12
pembrolizumab
12
Radiosurgery
12
Erlotinib Hydrochloride
12
fluorodopa F 18
11
Topotecan
11
Everolimus
11
Blood Specimen Collection
11
X-Rays
10
IL13-PE38
10
dabrafenib
9
Etoposide
9
ribociclib
8
poly ICLC
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Glioma
×
trastuzumab deruxtecan
×
Clear all
NCT05417594
2026-06-02
CERTIS1
AstraZeneca
Phase 1/2
Recruiting
695 enrolled